What is the price of Lazertinib on the market? Is one box expensive?

Lazertinib is a new third-generation EGFR tyrosine kinase inhibitor, mainly used to treat patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 19 deletion or exon 21 L858R mutation. The drug was approved by the US FDA for marketing in August 2024 under the trade name Lazcluze and is produced by Janssen Biotech. In Europe, lazertinib was approved in January 2025. Currently, Lazertinib is not yet available in China, so patients cannot purchase it domestically through formal channels.

In the United States, the price of lazertinib is higher. According to quotes from MedchemExpress, lazertinib is priced at $121 for the 5 mg strength, $204 for the 10 mg strength, $420 for the 50 mg strength, and $670 for the 100 mg strength. These prices are mainly suitable for scientific research use, and specific clinical drug prices may be higher. In addition, lazertinib is often combined with another drug, amivantamab, to form a chemotherapy-free combination treatment regimen. According to FDA approval information, lazertinib in combination with amivantamab has been approved for the first-time treatment of EGFR-mutated advanced or metastatic non-small cell lung cancer.

In China, lazertinib has not yet been approved by the National Medical Products Administration (NMPA) and therefore cannot be purchased through formal channels. Patients may need to purchase them through overseas medical institutions or pharmacies, but this involves high costs and a complicated purchase process. Since Lazertinib has not yet been included in China's medical insurance system, patients need to bear all costs out of pocket, which is a huge financial burden for most patients.
In general, Lazertinib, as a new type of EGFR inhibitor, has good efficacy, but its high price and the fact that it is not yet available on the market in China make patients face greater financial pressure when using this drug. When considering using this drug, patients should fully understand the relevant information and work with their doctor to develop a reasonable treatment plan. At the same time, patients and medical institutions should pay attention to the progress of lazertinib's launch in China so as to provide patients with better treatment options as soon as possible.
Reference: https://www.drugs.com/seladelpar.html